This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (33)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Cognitive Disorders  • Prognosis/ Outcomes  • Neuropathology  • Neurology, Other  • Aging/ Geriatrics  • Alert me on articles by topic

Anne M. Fagan, PhD; Catherine M. Roe, PhD; Chengjie Xiong, PhD; Mark A. Mintun, MD; John C. Morris, MD; David M. Holtzman, MD

Arch Neurol. 2007;64(3):343-349. Published online January 8, 2007 (doi:10.1001/archneur.64.3.noc60123).

Objectives  To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to discriminate early-stage Alzheimer disease (AD) (defined by clinical criteria and presence/absence of brain amyloid) from nondemented aging and to assess whether these biomarkers can predict future dementia in cognitively normal individuals.

Design  Evaluation of CSF β-amyloid₄₀ (Aβ₄₀), Aβ₄₂, tau, phosphorylated tau₁₈₁, and plasma Aβ₄₀ and Aβ₄₂ and longitudinal clinical follow-up (from 1 to 8 years).

Setting  Longitudinal studies of healthy aging and dementia through an AD research center.

Participants  Community-dwelling volunteers (n = 139) aged 60 to 91 years and clinically judged as cognitively normal (Clinical Dementia Rating [CDR], 0) or having very mild (CDR, 0.5) or mild (CDR, 1) AD dementia.

Results  Individuals with very mild or mild AD have reduced mean levels of CSF Aβ₄₂ and increased levels of CSF tau and phosphorylated tau₁₈₁. Cerebrospinal fluid Aβ₄₂ level completely corresponds with the presence or absence of brain amyloid (imaged with Pittsburgh Compound B) in demented and nondemented individuals. The CSF tau/Aβ₄₂ ratio (adjusted hazard ratio, 5.21; 95% confidence interval, 1.58-17.22) and phosphorylated tau₁₈₁/Aβ₄₂ ratio (adjusted hazard ratio, 4.39; 95% confidence interval, 1.62-11.86) predict conversion from a CDR of 0 to a CDR greater than 0.

Conclusions  The very mildest symptomatic stage of AD exhibits the same CSF biomarker phenotype as more advanced AD. In addition, levels of CSF Aβ₄₂, when combined with amyloid imaging, augment clinical methods for identifying in individuals with brain amyloid deposits whether dementia is present or not. Importantly, CSF tau/Aβ₄₂ ratios show strong promise as antecedent (preclinical) biomarkers that predict future dementia in cognitively normal older adults.

Author Affiliations: Departments of Neurology (Drs Fagan, Morris, and Holtzman), Biostatistics (Drs Roe and Xiong), Radiology (Dr Mintun), Pathology and Immunology (Dr Morris), and Molecular Biology and Pharmacology (Dr Holtzman), Hope Center for Neurological Disorders (Drs Fagan and Holtzman), and Alzheimer's Disease Research Center (Drs Fagan, Roe, Xiong, Mintun, Morris, and Holtzman), Washington University School of Medicine, St Louis, Mo.

RELATED LETTERS

Biomarkers in Dementia
, , , and
Arch Neurol. ;64():1356-1356.
FULL TEXT  

Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/beta-Amyloid42 Ratio

Arch Neurol. ;64():1357-1357.
FULL TEXT  

Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/beta-Amyloid42 Ratio Reply
, , , , , and
Arch Neurol. ;64():1357-1359.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition
Kauwe et al.
Proc. Natl. Acad. Sci. USA 2008;105:8050-8054.
ABSTRACT | FULL TEXT  

Amyloid {beta} Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization
Klyubin et al.
J. Neurosci. 2008;28:4231-4237.
ABSTRACT | FULL TEXT  

Expanding ventricles may detect preclinical Alzheimer disease
Weiner
Neurology 2008;70:824-825.
FULL TEXT  

Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice
Petrushina et al.
J. Neurosci. 2007;27:12721-12731.
ABSTRACT | FULL TEXT  

Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family
Brouwers et al.
Arch Neurol 2007;64:1436-1446.
ABSTRACT | FULL TEXT  

FLUCTUATIONS OF CSF AMYLOID-{beta} LEVELS: IMPLICATIONS FOR A DIAGNOSTIC AND THERAPEUTIC BIOMARKER
Shi and Bateman
Neurology 2007;69:1063-1065.
FULL TEXT  

Biomarkers in Dementia
Vanacore et al.
Arch Neurol 2007;64:1356-1356.
FULL TEXT  

Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/beta-Amyloid42 Ratio
Wong
Arch Neurol 2007;64:1357-1357.
FULL TEXT